Updated CDC HIV Testing Guidelines to Shape Evolving Diagnostics Market

Decision Resources
March 26, 2007
39 Pages - SKU: DECR1482745
License type:

HIV/AIDS stands out as a highly lucrative and expanding market for diagnostics companies because of the close integration of diagnostics in initial diagnosis and subsequent day-to-day disease management. With the newly released CDC screening recommendations advocating increased testing for the infection, diagnostics will play an increasingly critical role in HIV disease management.

Get the Answers You Need to Shape Your Strategy
  • The revised CDC guidelines for HIV testing are set to dramatically benefi t the HIV diagnostics market in the United States. Which sectors of the diagnostics market will benefi t most? What will be the long-term impact of the CDC recommendations?
  • The new recommendations have changed HIV testing from an "opt-in" diagnostic to an "opt-out" test that is a routine part of medical practice. How will this new process affect the diagnosis rates for HIV? Will it dramatically increase treatment rates?
  • HIV diagnosis is currently a multistep process that involves time-consuming confi rmatory tests. In its new recommendations, the CDC advocates the use of rapid testing. How will the CDC recommendations impact the rapid testing arena? Which companies are the key players in this sector?
  • With the increase in drug resistance among HIV/AIDS patients, resistance testing is playing a growing role in HIV disease management. Will the new CDC recommendations increase use of monitoring tests as well? What unmet needs remain in the resistance testing sector? Which companies are active in this area?
Please note, the PDF e-mail from publisher version of this report is for a global site license.